Clinical trial
A Non-interventional, Multi-centric, Single Country Observational Study to Assess the Safety and Effectiveness of Guselkumab After Ustekinumab (Originator or Biosimilar) in Moderate to Severe Psoriasis Patients in Clinical Routine
NCT07449234 is registered in ClinicalTrials.gov with Janssen-Cilag Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Non-interventional, Multi-centric, Single Country Observational Study to Assess the Safety and Effectiveness of Guselkumab After Ustekinumab (Originator or Biosimilar) in Moderate to Severe Psoriasis Patients in Clinical Routine
- Lead sponsor
- Janssen-Cilag Ltd.
- Phase
- Observational
- Overall status
- Terminated
- Start date
- February 9, 2026
- Completion date
- June 29, 2026
- Enrollment
- 9 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.